Immunogenicity and safety assessment of a SARS-CoV-2 recombinant spike RBD protein vaccine (Abdala) in paediatric ages 3–18 years old: a double-blinded, multicentre, randomised, phase 1/2 clinical trial (ISMAELILLO study)
-
Published:2023-09
Issue:
Volume:63
Page:102160
-
ISSN:2589-5370
-
Container-title:eClinicalMedicine
-
language:en
-
Short-container-title:eClinicalMedicine
Author:
Cinza-Estévez ZurinaORCID, Resik-Aguirre Sonia, Figueroa-Baile Nelvis L., Oquendo-Martínez Rachel, Campa-Legrá Ivan, Tejeda-Fuentes Alina, Rivero-Caballero Marila, González-García Gloria, Chávez-Chong Cristina O.ORCID, Alonso-Valdés Marel, Hernández-Bernal Francisco, Lemos-Pérez Gilda, Campal-Espinosa Ana, Freyre-Corrales Giselle, Benítez-Gordillo Delia, Gato-Orozco Evelyn, Pérez Bartutis Greter Susana, Mesa-Pedroso Iliana, Bueno-Alemani Nilda, Infante-Aguilar Elizabeth, Rodríguez Reinoso José Luis, Melo-Suarez Grettel, Limonta-Fernández Miladys, Ayala-Ávila Marta, Muzio-González Verena L., López-Machado M.A., Rodriguez D Alonso, Basulto-Puig J.C., Martin-Hernandez T., Sánchez-Miranda D., Agüero-Betancourt C.M., Besú-García B., Rodríguez-Fernández Y., Guerrero-Vega L., GómezFonseca I., Ramos-Pérez O., Acosta-Domínguez I., Ronquillo-Ramirez D., Díaz-Fernández Y., Aguilar-Soto L., Reíd-Montejo J., Palomo-Leyva Y., LandinFaria M.R., Rosendo-Domínguez R.M., Alonso-Manresa C., Marín-Pérez D.M., Malo-Lantigua Y., Rodríguez-Florat M.C., Delgado-Laborit Y., RodriguezGuevara Y., Peláez-González M., Torres-Mora Y., Cabrera-Hernández O.S., Gimarais-Varona F.J., Hormigot-Hernández M., Artola-Gutiérrez L.V., Gallardo-Martí L., Porro-Verdecia J., Castro-Bistorte R., RobertsDandie E., Berenguer-Pedroso S., Manso-García Yudith, Mora-García C.V., Lastre-Muñoz Y., Duran-Rivero O., Hernández-García B., Escobar-Escobar K., CarmenatesGutiérrez M.K., Conde-Bello B., Olazabal-Linares E.L., Bringas-Labrada I., Noy-León M., Velazco-González N., Bursosa-Moreno B., Morell-Padrón Y., Rodríguez-Matos Y., Treto-Torguet Y.M., Comas-Díaz L., Miranda F., FigueredoGonzález Y., Quiñones-Juan A., Mursuli-García I., Giménez-Velásquez V.M., Hernández-Ávila A., Hernández-Cabrera T., García-Zulueta T., Parra-Pérez A., Cintra-Jacob D., Mendoza-Jiménez M., de la Fuente-Carbonell S.M., Hernández-Eduard B., Ochoa-García M., Garcia-Iglesias E., Álvarez-Acosta A., Martínez-Rosales R.U., Ávila-Díaz L., Santana-Vázquez Z., Mila-Cáceres L., Guillén-Nieto G.E., Fuentes-Aguilar F., Nordelo-Valdivia A., GonzálezFernández N., González-Sarmientos M., Rubio-Salinas A., Domínguez-Rabilero L.C., Espinosa-Peña R.A., Ramírez-Núñez Y., Junco-Barranco J., Díaz-González O., Fragas-Quintero A., Pérez-Guevara M.T., Enriquez-Puertas J.M., Infante-Hernández Y., Cruz-Sui O., NoaRomero E., López Yizel Hernández, Sánchez-García J.E., Rodríguez-Martínez E., Pimentel-Vázquez E., Martínez-Díaz E.
Funder
National Center for Genetic Engineering and Biotechnology
Reference34 articles.
1. Weekly epidemiological update. Edition 115,2022 2. Interim statement on COVID-19 vaccination for children, 11 August 2022,2022 3. COVID-19 vaccine tracker,2022 4. COVID-19 vaccine effectiveness in adolescents aged 12– 17 years and interim public health considerations for administration of a booster dose,2022 5. Considering mandatory vaccination of children for COVID-19;Plotkin;Pediatrics,2021
|
|